At The Ohio State University Medical Center (OSUMC) Heart Transplant Program, we take pride in maintaining leading edge treatment methods and staying at the forefront of transplant research, as we have since our program started in 1986. With all transplant specialists together in one center, the patient is truly the focus of all care at Ohio State.
Ohio State’s team of researchers was among the first in the nation to evaluate the use of cyclosporine, a drug that suppresses the immune system and dramatically improves the success of organ transplantation.
Ohio State was also the fourth institution in the country certified to implant the temporary CardioWest™ Total Artificial Heart, which serves as a bridge to transplant for the most critically ill patients. There are currently 20 different mechanical systems used at OSUMC, with newer and smaller devices coming in the near future.
In addition, Ohio State's heart team has experience implanting a wide variety of left ventricular assist devices (LVADs) making us one of the top LVAD programs in the country. LVADs have been shown in clinical trials to significantly improve survival, heart function and quality of life in patients with end-stage heart failure.
Another example of leading edge treatment is AlloMap molecular testing currently available at Ohio State and a few other transplant centers. AlloMap is considered a breakthrough in determining a patient’s risk of rejection.
In addition to excellent patient care, enrollment of patients in clinical trials is 16 percent at Ohio State, which is higher than the national average.
Making more leading edge treatments available to patients is one of the many ways we strive to give each patient the best possible quality of life.